The estimated Net Worth of Carl Walkey is at least 5.15 百万$ dollars as of 16 June 2021. Dr Walkey owns over 600 units of Neoleukin Therapeutics stock worth over 4,720,187$ and over the last 4 years he sold NLTX stock worth over 425,653$.
Dr has made over 24 trades of the Neoleukin Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 600 units of NLTX stock worth 6,114$ on 16 June 2021.
The largest trade he's ever made was selling 3,000 units of Neoleukin Therapeutics stock on 10 February 2021 worth over 42,600$. On average, Dr trades about 1,245 units every 5 days since 2021. As of 16 June 2021 he still owns at least 1,352,489 units of Neoleukin Therapeutics stock.
You can see the complete history of Dr Walkey stock trades at the bottom of the page.
Dr. Carl Walkey Ph.D. is the Sr. VP of Corp. Devel. at Neoleukin Therapeutics.
Dr D is 36, he's been the Sr. VP of Corp. Devel. of Neoleukin Therapeutics since . There are 11 older and no younger executives at Neoleukin Therapeutics. The oldest executive at Neoleukin Therapeutics, Inc. is Lewis Williams, 70, who is the Independent Director.
Carl's mailing address filed with the SEC is CO NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE, WA, 98102.
Over the last 5 years, insiders at Neoleukin Therapeutics have traded over 425,653$ worth of Neoleukin Therapeutics stock and bought 6,490,231 units worth 38,477,971$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Group, Llc Green Jeremy Red...、Bros. Advisors Lp667, L.P.B.... On average, Neoleukin Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of 593,084$. The most recent stock trade was executed by Bros. Advisors Lp667, L.P.B... on 15 August 2023, trading 2,285,342 units of NLTX stock currently worth 1,462,619$.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Neoleukin Therapeutics executives and other stock owners filed with the SEC include: